KRRO Korro Bio, Inc.

NEUTRAL Impact: 3/10 Insider Cluster (2 insiders)
Horizon days Filed Jun 2, 2026 Processed 4d 11h ago
Insider cluster: 2 insiders, $231K total

Price Chart

Loading chart...

Executive Summary

Two insiders at Korro Bio, CEO Ram Aiyar and Director Jean Francois Formela, sold a combined $231K in open-market sales over two days. The CEO’s $197K sale represents roughly 0.1% of the $186M market cap, a modest amount that is routine relative to company size. No other material corporate events or filings accompany these sales, suggesting liquidity-driven or pre-scheduled dispositions rather than a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$230.7K
Insiders
2

Actionable Insight

Insider selling at this scale is too small to warrant a directional trade. Aiyar and Formela are significant shareholders; a single modest open-market sale by each is within normal liquidity patterns. Traders should focus on upcoming pipeline catalysts (phase data, trial updates) rather than this insider activity.

Key Facts

  • CEO Ram Aiyar sold 15,152 open-market shares on 2026-05-29 for ~$197K.
  • Director Jean Francois Formela sold 2,441 open-market shares on 2026-05-28 for ~$34K.
  • Combined $231K in sales equals ~0.12% of Korro Bio's $186M market cap.
  • No 10b5-1 plan designation is stated in the filings, but the modest dollar amounts and single-transaction-per-insider pattern are consistent with routine portfolio rebalancing or tax management.
  • No recent earnings, M&A, or regulatory catalyst was filed alongside this cluster.
  • The analyst consensus is heavily bullish (81% buy), contrasting with the insider activity.

Financial Impact

Total insider selling of $231K represents ~0.12% of market cap.

insider holdings

Risk Factors

  • If additional unannounced insider selling follows, the pattern could shift from routine to concerning.
  • No earnings or material event in the window; the lack of context makes these trades less informative.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
81% bullish (16 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KRRO-1780398034986
7 reports for KRRO
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for KRRO — sortable, filterable
Type Now
Jun 2, 2026
4d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+20
May 19, 2026
18d ago
8-K
BULLISH ★ 6/10
awaiting T+20
Apr 16, 2026
7w ago
DEFA14A
NEUTRAL ★ 3/10
$13.47 $11.20▼ −16.85%▼ −22.67%$10.72 (−20.42%)
Mar 23, 2026
10w ago
EFFECT
NEUTRAL ★ 4/10
$11.27 $13.49▲ +19.70%▲ +12.28%$10.72 (−4.88%)
Mar 13, 2026
12w ago
S-3
BEARISH ★ 7/10
$12.60 $13.93▼ −10.56%▼ −6.78%$10.72 (+14.92%)
Mar 10, 2026
12w ago
Insider Cluster
BULLISH ★ 8/10
$11.48 $13.46▲ +17.25%▲ +17.40%$10.72 (−6.62%)
Mar 9, 2026
12w ago
Press Release
NEUTRAL ★ 6/10
$12.30 $13.91▲ +13.09%▲ +15.90%$10.72 (−12.85%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (14h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access